PARP6 acts as a tumor suppressor via downregulating Survivin expression in colorectal cancer

Guangying Qi; Yasusei Kudo; Bo Tang; Tian Liu; Shengjian Jin; Jing Liu; Xiaoxu Zuo; Sisi Mi; Wenhuan Shao; Xiaojuan Ma; Takaaki Tsunematsu; Naozumi Ishimaru; Sien Zeng; Masaaki Tatsuka; Fumio Shimamoto

doi:10.18632/oncotarget.7712

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

PARP6 acts as a tumor suppressor via downregulating Survivin expression in colorectal cancer

Guangying Qi, Yasusei Kudo, Bo Tang, Tian Liu, Shengjian Jin, Jing Liu, Xiaoxu Zuo, Sisi Mi, Wenhuan Shao, Xiaojuan Ma, Takaaki Tsunematsu, Naozumi Ishimaru, Sien Zeng, Masaaki Tatsuka and Fumio Shimamoto _

PDF | HTML | How to cite

Oncotarget. 2016; 7:18812-18824. https://doi.org/10.18632/oncotarget.7712

Metrics: PDF 1955 views | HTML 5968 views | ?

Abstract

Guangying Qi1,2,*, Yasusei Kudo3,*, Bo Tang4,*, Tian Liu1, Shengjian Jin1, Jing Liu1, Xiaoxu Zuo1, Sisi Mi1, Wenhuan Shao1, Xiaojuan Ma1, Takaaki Tsunematsu3, Naozumi Ishimaru3, Sien Zeng1, Masaaki Tatsuka5, Fumio Shimamoto2

1Department of Pathology and Physiopathology, Guilin Medical University, Guilin 541004, People’s Republic of China

2Department of Health Sciences, Prefectural University of Hiroshima, Hiroshima 734-8558, Japan

3Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8504, Japan

4Department of Hepatobiliary Surgery, Affiliated Hospital of Guilin Medical University, Guilin 541000, People’s Republic of China

5Department of Life Sciences, Faculty of Life and Environmental Sciences, Prefectural University of Hiroshima, Hiroshima 727-0023, Japan

*These authors have contributed equally to this work

Correspondence to:

Sien Zeng, e-mail: [email protected]

Masaaki Tatsuka, e-mail: [email protected]

Fumio Shimamoto, e-mail: [email protected]

Keywords: PARP6, Survivin, colorectal cancer, tumor suppressor, prognosis

Received: January 15, 2016 Accepted: February 15, 2016 Published: February 25, 2016

ABSTRACT

Poly (ADP-ribose) polymerases (PARPs) are enzymes that transfer ADP-ribose groups to target proteins and are involved in a variety of biological processes. PARP6 is a novel member, and our previous findings suggest that PARP6 may act as a tumor suppressor via suppressing cell cycle progression. However, it is still unclear that PARP6 function besides growth suppression in colorectal cancer (CRC). In this study, we examined tumor suppressive roles of PAPR6 in CRC cells both in vitro and in vivo. We found that PARP6 inhibited colony formation, invasion and migration as well as cell proliferation. Moreover, ectopic overexpression of PARP6 decreased Survivin expression, which acts as an oncogene and is involved in apoptosis and mitosis. We confirmed the inverse correlation between PARP6 and Survivin expression in CRC cases by immunohistochemistry. Importantly, CRC cases with downregulation of PARP6 and upregulation of Survivin showed poor prognosis. In summary, PARP6 acts as a tumor suppressor via downregulating Survivin expression in CRC. PARP6 can be a novel diagnostic and therapeutic target together with Survivin for CRC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7712

Publication Alerts

Research Papers:

PARP6 acts as a tumor suppressor via downregulating Survivin expression in colorectal cancer

Abstract